ADMA Biologics (ADMA) Price & Analysis

Compare

2,975 Followers

ADMA Stock Chart & Stats

$17.70

-$0.24(-1.31%)

At close: Jan 08 4:00 PM EST

$17.70

-$0.24(-1.31%)

Day’s Range― - ―

52-Week Range$13.50 - $25.67

Previous CloseN/A

Volume407.39K

Average Volume (3M)2.21M

Market Cap

$4.35B

Enterprise Value$0.00

Total Cash (Recent Filing)$61.38M

Total Debt (Recent Filing)$83.12M

Price to Earnings (P/E)21.5

Beta0.87

Next Earnings

Mar 19, 2026

EPS Estimate

0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.16

Shares Outstanding237,997,770

10 Day Avg. Volume2,321,917

30 Day Avg. Volume2,207,994

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)11.45

Price to Sales (P/S)9.37

P/FCF Ratio36.31

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$30.00

Price Target Upside69.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.88

Revenue Forecast (FY)$631.85M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceADMA's underlying performance is strong, as evidenced by improved guidance for 2025 and 2026 following their earnings report.

Production OutputThe anticipated approval of Ig yield enhancement is expected to significantly increase production output, contributing to potential sales and margin growth.

Supply ChainThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.

Bears Say

Regulatory FilingADMA stated it would be unable to file its 2024 10-K within the prescribed timeframe.

ADMA Biologics News

Adma Biologics reports preliminary FY25 revenue $510M-$511M

“We are pleased with our performance in 2025 and the strong exit momentum we are carrying into 2026,”...

4d ago

ADMA

ADMA Biologics Inc. Reports Strong Q3 Earnings Call

ADMA Biologics Inc (($ADMA)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

ADMA

ADMA Biologics Reports Strong Q3 2025 Financial Results

ADMA Biologics Inc ( ($ADMA) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

ADMA

Adma Biologics reports Q3 EPS 15c, consensus 16c

Reports Q3 revenue $134.2M, consensus $130.53M. “ADMA is executing from a position of strength as we enter our...

2M ago

ADMA

Adma Biologics raises FY25 revenue view to at least $510M from at least $500M

Consensus $506.28M. Backs FY25 adjusted EBITDA view $235M. The company said, “In parallel, we continue to work towards...

2M ago

ADMA

Adma Biologics raises FY26 revenue view to at least $630M from up at least $625M

Consensus $637.85M. Raises FY26 adjusted EBITDA view to $355M from $340M. The company said, “ADMA‘s full-year 2025 and...

2M ago

ADMA

Adma Biologics options imply 14.3% move in share price post-earnings

Pre-earnings options volume in Adma Biologics (ADMA) is 9.4x normal with calls leading puts 8:3. Implied volatility suggests...

2M ago

ADMA

Adma Biologics management to meet virtually with Cantor

Virtual Meeting to be held on November 7 hosted by Cantor. Published first on TheFly – the ultimate...

2M ago

ADMA

Adma Biologics management to meet virtually with Cantor

Virtual Meeting to be held on November 10 hosted by Cantor. Published first on TheFly – the ultimate...

2M ago

ADMA

ADMA Upcoming Earnings Report: What to Expect?

ADMA Biologics Inc (ADMA) is scheduled to report 3rd quarter earnings on 11/05/2025, after the market closes. Regarding...

2M ago

ADMA

ADMA Biologics Earnings Call Highlights Robust Growth

ADMA Biologics Inc (($ADMA)) has held its Q2 earnings call. Read on for the main highlights of the...

5M ago

ADMA

ADMA Biologics Reports Strong Q2 2025 Results

ADMA Biologics Inc ( ($ADMA) ) has released its Q2 earnings. Here is a breakdown of the information...

5M ago

ADMA

Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings

In the opening 90 minutes of the evening session, U.S. equity futures are up slightly – S&P 500...

5M ago

ELF

MCK

ADMA Biologics Secures $300M Credit Agreement with JPMorgan

ADMA Biologics ( ($ADMA) ) has provided an update. On August 5, 2025, ADMA Biologics entered into a...

5M ago

ADMA

ADMA FAQ

What was ADMA Biologics Inc’s price range in the past 12 months?

ADMA Biologics Inc lowest stock price was $13.50 and its highest was $25.67 in the past 12 months.

What is ADMA Biologics Inc’s market cap?

ADMA Biologics Inc’s market cap is $4.35B.

When is ADMA Biologics Inc’s upcoming earnings report date?

ADMA Biologics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 62 days.

How were ADMA Biologics Inc’s earnings last quarter?

ADMA Biologics Inc released its earnings results on Nov 05, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.146 by $0.014.

Is ADMA Biologics Inc overvalued?

According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADMA Biologics Inc pay dividends?

ADMA Biologics Inc does not currently pay dividends.

What is ADMA Biologics Inc’s EPS estimate?

ADMA Biologics Inc’s EPS estimate is 0.19.

How many shares outstanding does ADMA Biologics Inc have?

ADMA Biologics Inc has 237,997,770 shares outstanding.

What happened to ADMA Biologics Inc’s price movement after its last earnings report?

ADMA Biologics Inc reported an EPS of $0.16 in its last earnings report, beating expectations of $0.146. Following the earnings report the stock price went down -8.718%.

Which hedge fund is a major shareholder of ADMA Biologics Inc?

Currently, no hedge funds are holding shares in ADMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ADMA Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

63.17%

Trailing 12-Months

Asset Growth

45.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics (ADMA) Earnings & Revenues

Historic Earnings Reports

ADMA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong overall performance with record revenue growth, successful product utilization, and promising future prospects. Despite some temporary challenges in the IVIG market and a negative margin plasma sale, the company's strategic initiatives and financial outlook are positive.View all ADMA earnings summaries

ADMA Stock 12 Month Forecast

Average Price Target

$30.00

▲(69.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","31":"$31","18.25":"$18.25","22.5":"$22.5","26.75":"$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,18.25,22.5,26.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.48,16.596923076923076,17.713846153846156,18.83076923076923,19.947692307692307,21.064615384615387,22.181538461538462,23.298461538461538,24.415384615384617,25.532307692307693,26.64923076923077,27.76615384615385,28.883076923076924,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.48,16.596923076923076,17.713846153846156,18.83076923076923,19.947692307692307,21.064615384615387,22.181538461538462,23.298461538461538,24.415384615384617,25.532307692307693,26.64923076923077,27.76615384615385,28.883076923076924,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.48,16.596923076923076,17.713846153846156,18.83076923076923,19.947692307692307,21.064615384615387,22.181538461538462,23.298461538461538,24.415384615384617,25.532307692307693,26.64923076923077,27.76615384615385,28.883076923076924,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >